| scholarly article | Q13442814 |
| P50 | author | Robin Murray | Q7352679 |
| Craig Morgan | Q39927282 | ||
| Martino Belvederi Murri | Q40573757 | ||
| Valeria Mondelli | Q42683658 | ||
| Paola Dazzan | Q46730140 | ||
| Marta Di Forti | Q46888593 | ||
| Tiago Reis Marques | Q47504367 | ||
| Patricia A Zunszain | Q47812812 | ||
| Carmine Pariante | Q49754517 | ||
| Simone Ciufolini | Q57614943 | ||
| Stefania Bonaccorso | Q114386388 | ||
| Annalisa Giordano | Q114452877 | ||
| P2860 | cites work | Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study | Q22251379 |
| High-potency cannabis and the risk of psychosis | Q24651025 | ||
| Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior | Q27694728 | ||
| Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update | Q28299995 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 | ||
| A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers | Q33587452 | ||
| Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume | Q33849008 | ||
| Remission in schizophrenia: proposed criteria and rationale for consensus | Q33985442 | ||
| Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics | Q33987036 | ||
| The link between childhood trauma and depression: insights from HPA axis studies in humans. | Q34012622 | ||
| A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism | Q34183522 | ||
| Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users | Q34322915 | ||
| A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression | Q34640047 | ||
| The cortisol awakening response (CAR): facts and future directions | Q34852491 | ||
| Childhood maltreatment predicts adult inflammation in a life-course study | Q35611661 | ||
| The stress cascade and schizophrenia: etiology and onset | Q35677879 | ||
| Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis | Q35768164 | ||
| Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis | Q36442025 | ||
| Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment | Q36442033 | ||
| Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis | Q36442053 | ||
| Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. | Q36539999 | ||
| Serum and gene expression profile of cytokines in first-episode psychosis | Q36910378 | ||
| Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia | Q37120692 | ||
| Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials | Q37228346 | ||
| White matter integrity as a predictor of response to treatment in first episode psychosis | Q37477310 | ||
| A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality | Q37798087 | ||
| Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis | Q37935296 | ||
| Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state | Q38015914 | ||
| A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis | Q38078110 | ||
| Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. | Q38128464 | ||
| Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. | Q38160607 | ||
| First-episode psychosis: an inflammatory state? | Q38189993 | ||
| Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors | Q38208771 | ||
| Cortical folding defects as markers of poor treatment response in first-episode psychosis | Q39366868 | ||
| Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis | Q39445647 | ||
| A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system | Q43754027 | ||
| Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change | Q44533519 | ||
| Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation | Q44870676 | ||
| Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. | Q45958452 | ||
| Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. | Q46178019 | ||
| The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. | Q47741981 | ||
| HPA axis response to social stress is attenuated in schizophrenia but normal in depression: evidence from a meta-analysis of existing studies | Q48207403 | ||
| Day differences in the cortisol awakening response predict day differences in synaptic plasticity in the brain. | Q48331548 | ||
| The effect of childhood trauma on pharmacological treatment response in depressed inpatients | Q48649240 | ||
| Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome | Q48721651 | ||
| Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. | Q49134812 | ||
| Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. | Q50773766 | ||
| The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. | Q51923075 | ||
| The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire | Q68918765 | ||
| Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers | Q69839595 | ||
| Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status | Q72006162 | ||
| Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs | Q79744901 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psychosis | Q170082 |
| inflammation | Q101991 | ||
| cortisol | Q190875 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 1162-1170 | |
| P577 | publication date | 2015-03-31 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis | |
| P478 | volume | 41 |
| Q87693377 | A Clinical Study Protocol to Identify Serum Biomarkers Predictive of Response to Antipsychotics in Schizophrenia Patients |
| Q92150502 | A History of Trauma is Associated with Aggression, Depression, Non-Suicidal Self-Injury Behavior, and Suicide Ideation in First-Episode Psychosis |
| Q58589435 | A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis |
| Q99604509 | A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach |
| Q39075961 | Abnormalities in chemokine levels in schizophrenia and their clinical correlates |
| Q51767689 | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. |
| Q47380198 | Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. |
| Q64070262 | Autoimmune Diseases and Psychotic Disorders |
| Q102369305 | Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation |
| Q38689600 | Brain microglia in psychiatric disorders |
| Q41611297 | Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations |
| Q92862577 | COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders |
| Q37349915 | Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report |
| Q57210509 | Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort |
| Q38716973 | Clinical Perspectives on Targeting Therapies for Personalized Medicine |
| Q90348369 | Commentary: Causal associations between inflammation, cardiometabolic markers and schizophrenia: the known unknowns |
| Q92462310 | Cytokine Alterations in Schizophrenia: An Updated Review |
| Q92197348 | Differential gene expression analysis in blood of first episode psychosis patients |
| Q38565570 | Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? |
| Q37349833 | HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis. |
| Q89848243 | Immuno-inflammatory changes across phases of early psychosis: The impact of antipsychotic medication and stage of illness |
| Q42378870 | Immuno-psychiatry: an agenda for clinical practice and innovative research |
| Q47746066 | Immunopsychiatry: important facts |
| Q39326557 | In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study |
| Q95500589 | Increased levels of midbrain immune-related transcripts in schizophrenia and in murine offspring after maternal immune activation |
| Q89976944 | Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study‡ |
| Q30236016 | Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization |
| Q39166258 | Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables |
| Q54237101 | Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. |
| Q46070080 | Inflammation, Stress Response, and Redox Dysregulation Biomarkers: Clinical Outcomes and Pharmacological Implications for Psychosis |
| Q99575601 | Inflammatory and Cardiometabolic Markers at Presentation with First Episode Psychosis and Long-term Clinical Outcomes: a longitudinal study using electronic health records |
| Q90835479 | Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls |
| Q57039667 | Intergenerational transmission of depression: clinical observations and molecular mechanisms |
| Q47155489 | Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? |
| Q57788867 | Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies |
| Q48071831 | Neuroscience, mental health and the immune system: overcoming the brain-mind-body trichotomy. |
| Q39346412 | Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis |
| Q33716543 | Pathways from Trauma to Psychotic Experiences: A Theoretically Informed Model of Posttraumatic Stress in Psychosis |
| Q64123533 | Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia |
| Q55353842 | Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study. |
| Q38624049 | Precision medicine for suicidality: from universality to subtypes and personalization. |
| Q64100900 | Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review |
| Q55016813 | Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: An electronic health record-based study. |
| Q47910090 | Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma? |
| Q60062678 | Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE) |
| Q37524068 | Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study |
| Q61447377 | Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study |
| Q38976291 | The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia |
| Q57471756 | The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial |
| Q38646326 | The blood-brain barrier in psychosis |
| Q47585327 | The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group |
| Q92480512 | The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research |
| Q33624412 | Theranostic Biomarkers for Schizophrenia |
| Q30363952 | Transcriptome sequencing of the choroid plexus in schizophrenia |
| Q40369760 | Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia |
| Q49343751 | Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances. |
| Q91782807 | Transposable Elements and Their Epigenetic Regulation in Mental Disorders: Current Evidence in the Field |
| Q89467779 | Trauma-informed care for adult survivors of developmental trauma with psychotic and dissociative symptoms: a systematic review of intervention studies |
| Q24289474 | Where Do Epigenetics and Developmental Origins Take the Field of Developmental Psychopathology? |
Search more.